Linked research, clinical, and regulatory source pathways.
Company profile
About EchoNous
EchoNous is a medical technology company pioneering AI-enhanced point-of-care ultrasound (POCUS) solutions. Founded in 2016 in Redmond, Washington, the company's name translates to 'intelligent sound' — combining echo (sound) with nous (intelligence) — reflecting its mission to integrate artificial intelligence with miniaturized ultrasound technology. EchoNous develops the Kosmos platform, which delivers cart-based ultrasound performance in a portable, handheld form factor. The platform features proprietary deep learning algorithms that provide real-time guidance for image acquisition and automated clinical measurements, enabling both novice and expert users to perform high-quality ultrasound examinations at the bedside. Kosmos offers advanced capabilities previously limited to larger systems, including Pulsed Wave (PW) Doppler, Continuous Wave (CW) Doppler, Tissue Doppler Imaging (TDI), and Color Doppler. The AI suite includes automated ejection fraction calculations, FAST exam anatomical labeling, bladder volume measurements, and auto-preset optimization across cardiac, lung, and abdominal applications. The company serves multiple clinical specialties including emergency medicine, critical care, cardiology, anesthesiology, nephrology, vascular access, family medicine, and OB/GYN. EchoNous manufactures its devices in the United States and maintains HIPAA and SOC2 compliance. The platform is compatible with proprietary displays as well as select Apple iOS and Android tablets, offering flexibility for clinical workflows. With a team comprising experts from ultrasound, AI, industrial design, and software engineering, EchoNous aims to make advanced diagnostic ultrasound accessible and actionable at the point of care.
Company description EchoNous official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Abdominal imaging
- Bladder volume assessment
- Cardiac function assessment
- Ejection fraction measurement
- FAST exam (trauma)
- Lung ultrasound
- Vascular access guidance
Who it serves
- Anesthesiology Departments
- Cardiology Practices
- Critical Care Units
- Emergency Departments
- Health Systems
- Nephrology Centers
- Primary Care Clinics
Deployment & integration
Deployment information is currently being developed.
Geographic context
Company milestones
Platform expansion
June 2026: Expanded Kosmos clinical capabilities with Vascular Auto Flow, advanced cardiac tools, and connectivity features. Launched Kosmos Bladder AI for automated bladder volume calculations. Introduced Kosmos EDU educational application for novice users.
Partnerships
Recorded partners
- 19 Labs
- Apple (iOS device compatibility)
- Us2.ai
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Diagnostic accuracy and cost-effectiveness of a handheld ultrasound device for cardiac evaluation in noncardiology settings.European heart journal. Imaging methods and practice · Jan 1, 2026
A SEMI-SUPERVISED JOINT LEARNING APPROACH TO LEFT VENTRICULAR SEGMENTATION AND MOTION TRACKING IN ECHOCARDIOGRAPHY.Proceedings. IEEE International Symposium on Biomedical Imaging · Apr 1, 2020
Unsupervised Motion Tracking of Left Ventricle in Echocardiography.Proceedings of SPIE--the International Society for Optical Engineering · Feb 1, 2020
Clinical validation
Clinical-trial records
Kosmos PLAX EF Pivotal StudyNCT07771231 · Sponsor · ACTIVE NOT RECRUITING
Kosmos Guidance Performance Evaluation Data AnnotationNCT07771270 · Sponsor · ACTIVE NOT RECRUITING
Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HFNCT06849752 · Sponsor · RECRUITING
Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart FailureNCT05705869 · Mentioned · ACTIVE NOT RECRUITING
ECHO-012 Kosmos Bladder Clinical Validation StudyNCT06792851 · Sponsor · COMPLETED
Kosmos Anatomical Object Labeling and View Identification Pivotal StudyNCT06468787 · Sponsor · COMPLETED
Regulatory
Regulatory records
KosmosK233826 · 510k · Aug 29, 2024
KosmosK212100 · 510k · Aug 6, 2021
KOSMOSK193518 · 510k · Mar 26, 2020
UscanK181574 · 510k · Jul 10, 2018
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
AI-assisted novice users achieving expert-level performance in cardiac assessments
Automated real-time cardiac function analysis at bedside
Complete cardiac exam performed by minimally trained user with AI guidance
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from EchoNous
Recent articles published on EchoNous's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.